{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:00:27Z","timestamp":1788102027177,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.diagmicrobio.2017.03.003","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T16:05:30Z","timestamp":1488989130000},"page":"184-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations"],"prefix":"10.1016","volume":"88","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1Q331","article-title":"Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem","volume":"46","author":"Brinkman","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0010","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2217\/fmb.15.53","article-title":"A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections","volume":"10","author":"Chan","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0015","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0020","series-title":"M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0025","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/AAC.02330-13","article-title":"Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival","volume":"58","author":"Corey","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0035","series-title":"ID Week, October 7\u201311, 2015. Abstr. 1519. San Diego, CA, USA","article-title":"A pilot study evaluating telavancin for the treatment of methicillin-resistant Staphylococcus aureus oteomyelitis: clinical outcomes and safety","author":"Harting","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0040","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1586\/eri.10.122","article-title":"Current medical management of diabetic foot infections","volume":"8","author":"Kosinski","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0045","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2014.12.006","article-title":"The clinical positioning of telavancin in Europe","volume":"45","author":"Masterton","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0055","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.04052-14","article-title":"Baseline activity of telavancin when tested against gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diagmicrobio.2014.12.011","article-title":"Update of the telavancin activity in vitro tested against a worldwide collection of gram-positive clinical isolates (2013), when applying the revised susceptibility testing method","volume":"81","author":"Mendes","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0065","article-title":"Telavancin activity tested against gram-positive clinical isolates from European, Russian and Israeli hospitals (2011\u20132013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin","author":"Mendes","year":"2015","journal-title":"Journal of chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0070","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1128\/AAC.04616-14","article-title":"Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jcpt.12030","article-title":"The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults","volume":"38","author":"Moenster","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0080","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/JCM.01210-14","article-title":"Quality control MIC ranges for telavancin with application of a revised CLSI reference broth microdilution method","volume":"52","author":"Ross","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0085","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14656566.2013.780596","article-title":"Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn","volume":"14","author":"Senneville","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0090","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0095","author":"VIBATIV Package Insert"},{"key":"10.1016\/j.diagmicrobio.2017.03.003_bb0100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jac\/dkn490","article-title":"Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model","volume":"63","author":"Yin","year":"2009","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317300792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317300792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T14:29:10Z","timestamp":1535984950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317300792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0732889317300792"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.03.003","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}